Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
56
datasets available to search
ShareScore release 0.9.0
Dataset results
56 results for “Vascular dementia”
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
ClinicalTrials.gov study NCT00947531. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
ClinicalTrials.gov study NCT06284213. IPD Sharing: YES. Countries: 1. Publications: 3.
Cog-VACCINE: Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia
ClinicalTrials.gov study NCT02640716. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.
ClinicalTrials.gov study NCT06903078. IPD Sharing: YES. Countries: 1. Publications: 6.
Dataset for research: "MTA and Koedam Score Contributes to Cognitive Impairment in Probable Alzheimer, Vascular and Mixed Dementia: A Memory Clinic Study in Indonesia"
<p>This is a dataset for research : "MTA and Koedam Score Contributes to Cognitive Impairment in Probable Alzheimer, Vascular and Mixed Dementia: A Memory Clinic Study in Indonesia"</p> <h1><strong><span>Abstract</span></strong></h1> <p><strong><span>Background</span></strong><span>. Medial Temporal Atrophy (MTA) and Parietal Atrophy (Koedam score) have been used in clinical practice to help the diagnosis of Alzheimer’s disease. However, the role of this brain imaging marker in early detection of other type of dementia remains elusive. The study aims to investigate the association between MTA and Koedam scores with the cognitive function in dementia patients (Alzheimer, vascular and mixed dementia).</span></p> <p><strong><span>Method</span></strong><span> <span>This was a</span> cross-sectional study using<span> data from a</span> Memory Clinic in Dr. Sardjito General Hospital Yogyakarta, Indonesia. The data was collected from January 2020 until December 2022. We collected the data regarding demographic and clinical characteristics, including head MRI data and Montreal Cognitive Assessment (MoCA) score. The cut-off points of MTA score and Koedam score were determined by using Receiver Operating Curve (ROC) and Youden Index. Multivariate analysis was performed to investigate variables which were associated with the cognitive function. </span></p> <p><strong><span>Result </span></strong><span>From 61 dementia patients, 22.95% was probable Alzheimer’s disease, 59.01% was vascular dementia, and 18.03% was mixed dementia. Correlation test showed that MTA and Koedam score were negatively associated with Montreal Cognitive Assessment-Indonesian Version (MoCA-INA) score. A bivariate analysis supports the findings that patients with combination of MTA score ≥3 and Koedam score ≥2 was more likely to have poor cognitive function (OR= 11.33; p<0.05). Multivariate analysis showed higher MTA (≥3) and Koedam (≥2) scores were associated with poor cognitive function in dementia patients (OR= 13.54, 95% CI= 1.77-103.43, <em>p</em>=0.01 and OR= 5.52, 95% CI= 1.08-28.19, <em>p</em>=0.04)</span></p> <p><strong><span>Conclusion </span></strong><span>Higher MTA and Koedam score contribute to worse cognitive function in any type of dementia patients. </span></p> <p><strong><span>Keywords.</span></strong><span> Imaging Marker, Medial Temporal Atrophy (MTA), Koedam Score, Cognitive Function, Dementia</span></p>
Vascular mEchanisms in, Stroke, dePression, dementiA, and deliRum: The VESPAR Project
ClinicalTrials.gov study NCT05649800. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
ClinicalTrials.gov study NCT02453932. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia
ClinicalTrials.gov study NCT03230071. IPD Sharing: NO. Countries: 1. Publications: 1.
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
ClinicalTrials.gov study NCT06507488. IPD Sharing: YES. Countries: 1. Publications: 24.
Aricept to Improve Functional Tasks in Vascular Dementia
ClinicalTrials.gov study NCT00457769. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
ClinicalTrials.gov study NCT00847860. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Remote Ischemic Preconditioning for Subcortical Vascular Dementia
ClinicalTrials.gov study NCT03022149. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
ClinicalTrials.gov study NCT00099216. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
ClinicalTrials.gov study NCT01761227. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia
ClinicalTrials.gov study NCT01363648. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Vascular Cognitive Decline and Dementia
ClinicalTrials.gov study NCT06257823. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: Increased CAIDE dementia risk, cognition, CSF biomarkers and vascular burden in healthy adults
Objective: To investigate the cognitive profile of healthy individuals with increased CAIDE dementia risk score, and to explore whether this association is related to vascular burden and CSF biomarkers of amyloidosis and neurodegeneration. Method: Cognitively normal participants (mean age = 57.6 years) from the Gipuzkoa Alzheimer Project study were classified as having high risk (HR, n = 82) or low risk (LR, n = 293) for dementia according to a CAIDE score cut off of 9. Cognitive composites were compared between groups. We explored the role of APOE genotype, MRI white matter hyperintensities (WMH) and CSF (n = 218) levels of amyloid-β1-42 (Aβ1-42), total tau (t-tau) and phosphorylated tau (p-tau) in the association between CAIDE and cognition conducting generalized linear models. Results: HR participants obtained lower scores on executive function (EF) (p = .001) and visual perception and construction (VPC) (p < .001) composites. EFc was associated with CAIDEp-tau (p = .001), CAIDEt-tau (p = .001) and WMH (p = .003). VPCc was associated with APOE (p = .001), Aβ1-42 (p = .004), the interaction APOEAβ1-42 (p = .003), and WMH (p = .004). Performance on global memory was associated with Aβ1-42 (p = .006), APOE (p = .008), and their interaction (p = .006). Analyses were adjusted for age, education, sex, premorbid intelligence and stress. Conclusion: Healthy participants at increased dementia risk, based on CAIDE scores, show lower performance in executive function and visual perception and construction. This difference is related to APOE, WMH and Alzheimer's biomarkers.
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
ClinicalTrials.gov study NCT00261573. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
ClinicalTrials.gov study NCT00174382. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
ClinicalTrials.gov study NCT04552041. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.